-- Global preclinical CRO Ace Therapeutics expands its cardiovascular disease model portfolio with fully validated myocardial ischemia-reperfusion (MI/R) animal modeling services, equipping academic labs and biopharma developers with reproducible research tools to advance ischemic cardiomyopathy therapeutic discovery.
Surgical coronary artery ligation remains the gold-standard method to recapitulate human heart attack and reperfusion therapy pathology. Ace Therapeutics optimizes every procedural step for consistent, customizable model generation. Under deep anesthesia, Ace Therapeutics’ experts perform thoracotomy, temporary ligation of the left anterior descending coronary artery, timed ischemia incubation, suture release for reperfusion, followed by chest closure and layered skin closure. Post-operative continuous animal monitoring mitigates infection, organ failure, and premature mortality, ensuring intact study cohorts for long-term efficacy and mechanistic readouts.
The custom coronary artery ligation MI/R models cover a broad panel of validated animal strains to match diverse research design requirements, including C57BL/6 and BALB/c mice, SD and Wistar rats, alongside New Zealand white and Japanese white rabbits. Rigorous multi-layered model validation protocols guarantee a reliable ischemic injury phenotype: real-time intraoperative ECG monitoring tracks ST-segment elevation as an immediate marker of successful coronary occlusion, while terminal myocardial tissue harvest paired with TTC-Evans blue dual staining enables precise quantitative calculation of infarct area, delivering objective histological endpoints for drug comparison.
As scalable preclinical anti-ischemic drug efficacy evaluation models, these MI/R models support full-spectrum research workflows ranging from basic mechanistic pathway exploration to candidate compound pharmacodynamic screening. Researchers leverage the standardized surgical models to investigate signaling pathways governing ischemic preconditioning and reperfusion cytoprotection, quantify drug-mediated reductions in infarct size, and assess therapeutic impacts on oxidative stress, inflammatory signaling, and cardiomyocyte survival. All modeling procedures align with published cardiovascular research frameworks and peer-reviewed experimental protocols, delivering comparable, publication-quality datasets for preclinical IND-enabling studies.
Ace Therapeutics has long specialized in custom cardiovascular disease animal model development, maintaining a full-service platform spanning atherosclerosis, hypertension, thrombosis, heart failure, and now refined MI/R injury systems. The launch of its standardized validated custom MI/R models fills a critical gap for partners seeking turnkey, validated preclinical anti-ischemic drug efficacy evaluation models without the resource burden of in-house surgical model optimization. Its integrated service package covers full model construction, intraoperative physiological monitoring, post-operative animal care, tissue collection, histochemical staining, and quantitative infarct analysis, streamlining end-to-end cardiovascular preclinical testing.
Investigators and pharmaceutical developers focused on myocardial protection, anti-infarction, and reperfusion injury therapies can access Ace Therapeutics' complete animal models of cardiovascular disease for customized study design. Its cross-disciplinary team of cardiovascular pharmacologists, veterinary surgeons, and pathologists tailors model parameters—including ischemia duration, reperfusion timeline, and species selection—to match unique research hypotheses and drug development milestones.
About Ace Therapeutics
Ace Therapeutics is a leading provider of cardiovascular basic research services and custom preclinical animal model development. Its comprehensive disease model library enables translational research and drug efficacy assessment for ischemic heart disease, metabolic cardiovascular disorders, and chronic heart failure, supporting global academic institutions, biotech startups, and pharmaceutical enterprises in advancing novel cardiovascular therapeutics.
Contact Info:
Name: Daisy Mostert
Email: Send Email
Organization: Ace Therapeutics
Website: https://www.acetherapeutics.com/cardiovascular-diseases/
Release ID: 89198750
Google
RSS